VALNEVA SE (VLA.PA) Stock Price, Forecast & Analysis
Europe - EPA:VLA - FR0004056851 - Common Stock
VLA.PA Key Statistics, Chart & Performance
The current stock price of VLA.PA is 3.866 EUR. In the past month the price decreased by -11.04%. In the past year, price increased by 77.34%.
VLA.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 73.08 | 48.01B | ||
| 1AE.DE | ARGENX SE | 72.09 | 47.36B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.63B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.33B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.33B | ||
| GLPG.AS | GALAPAGOS NV | 24.38 | 1.80B | ||
| 5CV.DE | CUREVAC NV | 5.24 | 1.03B | ||
| NANO.PA | NANOBIOTIX | N/A | 876.56M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| IVA.PA | INVENTIVA SA | N/A | 494.46M | ||
| FYB.DE | FORMYCON AG | N/A | 366.65M | ||
| ALCLS.PA | CELLECTIS | N/A | 341.61M |
Related stock screener links
About VLA.PA
Company Profile
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 700 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Company Info
VALNEVA SE
6 rue Alain Bombard
Saint-Herblain PAYS DE LA LOIRE FR
Employees: 713
Phone: 33228073710
VALNEVA SE / VLA.PA FAQ
Can you describe the business of VALNEVA SE?
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 700 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
What is the stock price of VALNEVA SE today?
The current stock price of VLA.PA is 3.866 EUR. The price decreased by -2.52% in the last trading session.
What is the dividend status of VALNEVA SE?
VLA.PA does not pay a dividend.
How is the ChartMill rating for VALNEVA SE?
VLA.PA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is VLA.PA stock listed?
VLA.PA stock is listed on the Euronext Paris - Matif exchange.
What is VALNEVA SE worth?
VALNEVA SE (VLA.PA) has a market capitalization of 332.16M EUR. This makes VLA.PA a Small Cap stock.
Who owns VALNEVA SE?
You can find the ownership structure of VALNEVA SE (VLA.PA) on the Ownership tab.
VLA.PA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to VLA.PA. When comparing the yearly performance of all stocks, VLA.PA is one of the better performing stocks in the market, outperforming 90.53% of all stocks.
VLA.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VLA.PA. Both the profitability and financial health of VLA.PA have multiple concerns.
VLA.PA Financial Highlights
Over the last trailing twelve months VLA.PA reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by -95.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| Debt/Equity | 0.8 |
VLA.PA Forecast & Estimates
11 analysts have analysed VLA.PA and the average price target is 7.17 EUR. This implies a price increase of 85.44% is expected in the next year compared to the current price of 3.866.
For the next year, analysts expect an EPS growth of -619.37% and a revenue growth -3.79% for VLA.PA